A carregar...
Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
The optimal management of advanced non‐small cell lung cancer (NSCLC) with noncanonical epidermal growth factor receptor (EGFR) mutations (i.e., exon 19 deletion and exon 21 L858R) is constrained by the heterogeneous behavior of individual uncommon mutations and limited prospective clinical data in...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8018319/ https://ncbi.nlm.nih.gov/pubmed/32969527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13537 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|